Z51.89 Insurance Policy Changes

ICD-10 Z51.89 is officially defined as "Encounter for other specified aftercare." code Z51.89 is referenced in 12 tracked payer policy changes from Aetna and Blue Cross & Blue Shield of Mississippi. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code Z51.89 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Aetna · Identified Nov 2, 2026Medium impact
Robotic-assisted Rehabilitation of the Extremities (CPB 0778, reviewed 2026-10-28)
Aetna reviewed its clinical policy bulletin on robotic-assisted rehabilitation of the arms and legs (CPB 0778) on 2026-10-28. The bulletin treats robotic-assisted rehab for humeral fracture, incomplete spinal cord injury, neuromuscular disease, stroke and traumatic brain injury as experimental or unproven, and lists named devices such as IDEO, Myomo, IpsiHand, Motus, Obi, powered hip orthoses, Trexo, Walkbot and Kinova JACO as not covered. The source does not state an effective date for any change or say what changed from the prior version.
Aetna · Identified Aug 17, 2026Medium impact
Grenz Ray Therapy for Skin Disorders (CPB 0231, reviewed 2026-04-13)
Aetna considers Grenz ray therapy experimental, investigational, or unproven for treating dermatologic conditions, because the published peer-reviewed literature has inadequate evidence of its effectiveness for skin disorders. Grenz rays are x-rays and should be treated with the same caution as other ionizing radiation. CPT 96900 (actinotherapy) is listed as not covered for the listed indications, and unlisted code 77499 is required for Grenz ray therapy. Last reviewed 04/13/2026, with the next review set for 02/25/2027.
Aetna · Identified Aug 14, 2026Medium impact
Voice Therapy (CPB 0646, reviewed 2025-12-08)
Aetna considers voice therapy medically necessary to restore the ability to produce speech sounds from the larynx for essential voice tremor, surgery or traumatic injury to the vocal cords, treatment for laryngeal (glottic) carcinoma, muscle tension dysphonia, paradoxical vocal cord motion, post-laryngectomy esophageal speech production, spastic dysphonia, symptomatic benign vocal fold lesions, and vocal cord paralysis. Voice therapy is not medically necessary to improve voice quality, for occupational or recreational purposes, or for self-limited conditions such as acute laryngitis, and maintenance treatment where symptoms are not improving is not medically necessary. Pre-operative voice therapy for improving outcomes of surgery for benign vocal fold lesions, and voice therapy for vocal fold motion impairment following chemotherapy, are considered experimental, investigational, or unproven.
Aetna · Identified Aug 14, 2026Medium impact
Intensive Cardiac Rehabilitation Programs (CPB 0267, reviewed 2026-05-14)
Aetna considers intensive cardiac rehabilitation programs (the Benson-Henry Institute Cardiac Wellness Program, the Ornish cardiac treatment program and the Pritikin Program) medically necessary as an alternative to traditional Phase II cardiac rehabilitation for members who meet the cardiac rehabilitation criteria, limited to 72 one-hour sessions, up to 6 per day, over a period of up to 18 weeks. Virtual delivery by real-time audio and video (excluding audio-only) is considered medically necessary when the telehealth program and member criteria are met, but hospital outpatient departments are not eligible for virtual telehealth services. Intensive cardiac rehabilitation is considered experimental, investigational or unproven for diabetes, hyperlipidemia, prostate cancer, metabolic syndrome and all other indications where effectiveness has not been established.
Aetna · Identified Aug 14, 2026Medium impact
Intestinal Rehabilitation Programs (CPB 0342, reviewed 2026-05-21)
As last reviewed on May 21, 2026, Aetna considers multidisciplinary intestinal rehabilitation programs medically necessary for persons with parenteral nutrition-dependent intestinal failure. These programs usually include a team of dietitians, nurses, gastroenterologists, neonatologists and pediatric surgeons, and focus on diet and nutrition, medications, surgery and rehabilitation. Aetna considers intestinal rehabilitation programs experimental, investigational or unproven for all other indications.
Aetna · Identified Aug 13, 2026Medium impact
Pool Therapy, Aquatic Therapy or Hydrotherapy (CPB 0174, reviewed 2026-04-21)
Aetna considers aquatic therapy (hydrotherapy, pool therapy) medically necessary for osteoarthritis of the knee or hip, fibromyalgia, ankylosing spondylitis, rheumatoid arthritis, chronic low back pain, or other musculoskeletal conditions when pain, weight-bearing restrictions or poor balance prevent the member from pursuing land-based therapeutic activities or exercises. Aquatic therapy that maintains a level of function, where the member is neither improving nor regressing, is considered not medically necessary. Pool therapy is considered experimental, investigational or unproven for post-stroke pain, asthma and other non-musculoskeletal indications, including stroke rehabilitation, and it is a physical therapy modality subject to physical therapy guidelines and plan benefit limits.
Aetna · Identified Aug 12, 2026Medium impact
Omalizumab (CPB 0670, reviewed 2026-06-05)
Aetna Clinical Policy Bulletin 0670 covers omalizumab (Xolair) and omalizumab-igec (Omlyclo) for commercial medical plans, and precertification is required for these products in applicable plan designs. Aetna considers omalizumab medically necessary for asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), chronic spontaneous urticaria, IgE-mediated food allergy, immune checkpoint inhibitor-related toxicity and systemic mastocytosis when the listed criteria are met. Aetna considers all other indications experimental, investigational or unproven, and the Site of Care Utilization Management Policy applies to these products.
Aetna · Identified Aug 12, 2026Medium impact
Occupational Therapy (CPB 0250, reviewed 2026-05-19)
Aetna considers short-term occupational therapy medically necessary when a physician prescribes it and the member's condition can improve based on objective measures within 1 month of starting therapy, or when the therapy is needed to establish a maintenance program. Occupational therapy is considered not medically necessary once maximal therapeutic benefit has been achieved, when the condition is neither regressing nor improving, or when the member has no identifiable clinical condition. Treatments intended to improve instrumental activities of daily living, such as community living skills, home management, and leisure activities, are not covered.
Aetna · Identified Aug 12, 2026Medium impact
Behavioral Vision Therapy and Vision Restoration Therapy (CPB 0321, reviewed 2026-05-21)
Aetna considers behavioral vision therapy, also called visual perceptual training, experimental, investigational, or unproven for visual perceptual dysfunctions and for all other indications, including body dysmorphic disorder and reading or spelling disorders, because its effectiveness has not been validated in well-designed prospective clinical studies. Aetna considers vision restoration therapy experimental, investigational, or unproven for visual field deficits due to ischemic optic neuropathy, neurotrauma, or stroke and for all other indications. Aetna also considers vision restoration therapy, alone or with transcranial direct current stimulation, experimental, investigational, or unproven for visual field deficits following stroke or neurotrauma.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Orthoptic Training for the Treatment of Vision or Learning Disabilities
Orthoptic eye exercises for the treatment of learning disabilities are considered investigational, and vision therapy and orthoptics for dyslexia and other learning and reading disabilities are considered investigational. Vision therapy that involves occlusion as treatment for amblyopia, and vision therapy that involves prism adaptation before surgery for acquired esotropia, are considered medically necessary. Office-based vergence or accommodative therapy may be considered medically necessary for symptomatic convergence insufficiency if symptoms have failed to improve after a minimum of 12 weeks of home-based therapy.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Neuromuscular Electrical Stimulation (NMES)
Neuromuscular electrical stimulation is covered only where the nerve supply to the muscle is intact, for muscle strengthening or retraining for disuse atrophy after prolonged immobilization, surgery or injury, and for other non-neurological reasons for disuse-causing atrophy. High voltage pulsed current may also be covered to reduce swelling and control pain, but its use for wounds and ulcers is investigational, as is NMES for multiple sclerosis, Bell's palsy, other motor function or motor nerve disorders, wounds and ulcers, and scoliosis. The policy review dated 07/01/2026 left the policy statements unchanged and removed ICD-9 diagnosis codes from the code reference section.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Allergy Immunotherapy
Allergen immunotherapy is paid by injection, not by dose, and provision of antigens is paid by dose or vial based on the CPT descriptor. Immunotherapy is considered medically necessary in patients with demonstrated hypersensitivity that cannot be managed by medications or avoidance. Sublingual immunotherapy, provocative and neutralization therapy for food allergies using intradermal and subcutaneous routes, urine autoinjections, and repository emulsion therapy are investigational and not covered. Clinical ecology services are investigational even when billed as allergy services, and allergen-proof supplies such as mattresses, pillows and air purification devices are considered personal convenience items.

Watch Z51.89

Get one email when a payer policy names Z51.89, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code Z51.89?

There are 12 tracked policy changes affecting code Z51.89, including updates from Aetna, Blue Cross & Blue Shield of Mississippi. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code Z51.89?

Payers that have issued tracked updates for code Z51.89 include: Aetna, Blue Cross & Blue Shield of Mississippi.

How do I get notified when code Z51.89 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code Z51.89. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code Z51.89?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Robotic-assisted Rehabilitation of the Extremities (CPB 0778, reviewed 2026-10-28)

Grenz Ray Therapy for Skin Disorders (CPB 0231, reviewed 2026-04-13)

Voice Therapy (CPB 0646, reviewed 2025-12-08)

Intensive Cardiac Rehabilitation Programs (CPB 0267, reviewed 2026-05-14)

Intestinal Rehabilitation Programs (CPB 0342, reviewed 2026-05-21)

Pool Therapy, Aquatic Therapy or Hydrotherapy (CPB 0174, reviewed 2026-04-21)

Omalizumab (CPB 0670, reviewed 2026-06-05)

Occupational Therapy (CPB 0250, reviewed 2026-05-19)

Behavioral Vision Therapy and Vision Restoration Therapy (CPB 0321, reviewed 2026-05-21)

Orthoptic Training for the Treatment of Vision or Learning Disabilities

Neuromuscular Electrical Stimulation (NMES)

Allergy Immunotherapy

What insurance policy changes affect code Z51.89?

Which payers have updated policy for code Z51.89?

How do I get notified when code Z51.89 policy changes?

Why do payers change policies for code Z51.89?